Purple Biotech (PPBT) EBITDA (2014 - 2026)

Purple Biotech (PPBT) has 13 years of EBITDA data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, EBITDA rose 60.1% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $28.3 million, a 253.18% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, up 149.5% from the prior year.
• EBITDA for Q1 2026 stood at $2.3 million, down from $23.4 million in the prior quarter.
• Over the last five years, EBITDA for PPBT reached as high as $23.4 million in Q4 2025 and fell as low as $1.0 million in Q4 2024.
• Historically, EBITDA has averaged $5.0 million across 5 years, with a median of $4.5 million in 2024.
• Across the five-year window, EBITDA sank 83.79% in 2024 and surged 2207.68% in 2025, its largest moves.
• Year by year, EBITDA stood at $6.6 million in 2022, then decreased by 5.06% to $6.3 million in 2023, then sank by 83.79% to $1.0 million in 2024, then jumped by 2207.68% to $23.4 million in 2025, then slumped by 90.4% to $2.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $2.3 million in Q1 2026, $23.4 million in Q4 2025, and $1.4 million in Q3 2025.